Research programme: kallikrein inhibitors - BioCryst

Drug Profile

Research programme: kallikrein inhibitors - BioCryst

Latest Information Update: 20 Dec 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioCryst Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Bradykinin inhibitors; Kallikrein inhibitors; Tissue factor-factor VIIa complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hereditary angioedema
  • Discontinued Acute coronary syndromes; Cancer; Coronary artery restenosis

Most Recent Events

  • 20 Dec 2013 Preclinical trials in Hereditary angioedema in USA (PO)
  • 28 Mar 2013 Early research in Hereditary angioedema in USA (PO)
  • 07 Dec 2012 BioCryst announces the company's strategic restructuring with focus on advancement of its hereditary angioedema programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top